YOLFTbeta
Boundless Bio, Inc. Common Stock

Boundless Bio, Inc. Common Stock

BOLD · NASDAQ · Healthcare / Biotechnology

2.50USD+0.04 (+1.63%)

Price History

Full chart

Market Stats

Previous Close2.46
Open2.46
Day Range2.39 – 2.54
52-Week Range0.9612 – 3.16
Volume156.47K
Market Cap59.14M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.74
Dividend Yield0.00%
Beta0.44
50-Day Avg2.75
200-Day Avg1.75

About

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Jessica Oien J.D.
  • Employees28
  • Headquarters10955 Alexandria Way, San Diego, CA, United States, 92121, USA
  • Websitehttps://boundlessbio.com

Leadership

  • Ms. Jessica Oien J.D.President, Principal Executive Officer, Chief Legal Officer & Corporate Secretary · b. 1971
  • Mr. David HinkleSenior VP of Finance, Controller & Corporate Treasurer · b. 1962
  • Ms. Meredith WesleyChief Human Resources Officer

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---00000
Cost of Revenue---682.00K942.00K957.00K1.09M1.25M
Gross Profit----682.00K-942.00K-957.00K-1.09M-1.25M
Operating Expense---24.62M45.53M53.84M72.18M62.30M
Operating Income-60.05M-93.18M-134.37M-25.30M-46.47M-54.80M-73.27M-63.55M
EBITDA-58.09M-88.74M-121.36M-24.53M-44.96M-48.48M-64.28M-56.95M
Net Income-59.67M-90.24M-128.82M-25.21M-45.90M-49.43M-65.36M-58.20M
R&D48.77M75.90M104.37M19.28M37.16M42.64M55.27M44.84M

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets142.06M178.66M472.56M113.72M76.83M129.89M206.41M157.06M
Total Liabilities22.69M22.06M29.80M151.91M158.53M256.98M55.77M58.41M
Total Equity119.37M156.60M442.75M-38.19M-81.70M-127.08M150.64M98.65M
Cash36.36M38.97M144.35M34.29M10.95M23.71M26.59M17.87M
Total Debt2.75M7.18M7.07M377.00K5.18M2.19M47.63M49.03M
Net Debt-33.61M-31.79M-137.28M-33.91M-5.77M-21.51M21.05M31.17M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-49.02M-84.51M-107.98M-23.25M-39.60M-46.85M-60.84M-46.66M
Investing Cash Flow-62.05M-33.44M-185.05M-59.28M16.13M-38.26M-26.10M37.80M
Financing Cash Flow75.36M120.55M398.46M105.53M126.00K97.90M89.82M141.00K
Capital Expenditure16.65M7.55M11.61M2.03M1.07M633.00K2.54M546.00K
Free Cash Flow-65.67M-92.06M-119.59M-25.28M-40.66M-47.49M-63.38M-47.21M
FCF to OCF133.97%108.94%110.75%108.75%102.69%101.35%104.17%101.17%

Earnings

Report DateAug 31, 2016Nov 10, 2016Mar 9, 2017May 11, 2017Aug 10, 2017Nov 14, 2017Mar 8, 2018May 9, 2018Aug 7, 2018Nov 6, 2018Feb 27, 2019May 7, 2019Aug 6, 2019Nov 7, 2019Feb 28, 2024May 13, 2024Aug 12, 2024Nov 7, 2024Mar 27, 2025May 9, 2025Aug 5, 2025Nov 5, 2025Mar 26, 2026May 8, 2026Aug 7, 2026Nov 4, 2026
EPS Estimate-1.33-0.65-0.75-0.92-0.79-0.89-0.90-0.80-0.78-0.88-0.91-0.89-1.04-1.070.00-0.45-0.81-0.74-0.84-0.73-0.65-0.53-1.16-0.51-0.58-
EPS Actual-6.43-0.94-0.91-0.83-0.87-0.88-0.82-0.74-0.85-0.97-0.84-1.13-1.01-1.00-9.76-12.27-0.77-0.74-0.74-0.71-0.70-0.62-0.58-0.60-1.06-
Surprise-383.46%-44.62%-21.33%9.78%-10.13%1.12%8.89%7.50%-8.97%-10.23%7.69%-26.97%2.88%6.54%--2626.67%4.94%0.00%11.90%2.74%-7.69%-16.98%50.00%-17.65%-82.76%-
TimingAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketAfter-hoursAfter-hours-Pre-marketPre-marketPre-market-Pre-market--

Key Statistics & Ratios

Market Cap59.14M
Enterprise Value-11.21M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.93
EPS-2.74
Book Value2.94
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-64.23M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-67.86%
Return on Assets-32.77%
Shares Outstanding22.75M
Shares Float16.08M
Beta0.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 3 analystsTarget 4.00
  • Buy
    1
  • Hold
    2

Ownership Breakdown

Institutions
67.26%
Insiders
12.09%
Retail / Other
20.65%

Top Institutional Holders

  • FMR Inc
    2.70M11.85%
  • ARCH VENTURE CORP
    2.69M11.84%
  • Stonepine Capital Management Llc
    597.68K2.63%
  • Vanguard Capital Management, LLC
    597.19K2.63%
  • Wellington Management Company LLP
    556.23K2.45%
  • Millennium Management LLC
    478.64K2.10%
  • Renaissance Technologies Corp
    399.00K1.75%
  • Alyeska Investment Group, L.P.
    300.00K1.32%
  • Affinity Asset Advisors, LLC
    250.00K1.10%
  • RBF LLC
    200.00K0.88%
  • Ensign Peak Advisors Inc
    187.50K0.82%
  • Citadel Advisors Llc
    145.05K0.64%
  • Geode Capital Management, LLC
    127.58K0.56%
  • GSA Capital Partners LLP
    72.35K0.32%
  • BlackRock Inc
    70.67K0.31%

Top Fund Holders

  • Fidelity Growth Company Fund
    899.16K3.95%
  • Vanguard MStar Total Stk Mkt Idx Invest
    445.18K1.96%
  • Fidelity Growth Company K6
    227.61K1.00%
  • Fidelity Series Growth Company
    199.72K0.88%
  • Bridgeway Ultra-Small Company
    77.50K0.34%